webinar register page

Webinar banner
Cell & Gene Therapy: How should curative medicines be valued and priced?
Advances in cell and gene therapies have provided breakthroughs in curing previously incurable diseases. The last five years have witnessed much-anticipated launches of drugs such as Kymriah (for leukemia) and Zolgensma (for spinal muscular atrophy). However, the industry is still unsure about how will these advanced therapies be valued by the patients and healthcare providers. To discuss more the recent developments and prospects of cell and gene therapy drugs, join us for a fireside chat with Jessica Turner on 27.05.2020 at 6.30 PM (Israel time).

The session will comprise of a ~20 min presentation on advances and challenges of cell & gene therapy followed by ~40 min of discussion with the participants. Feel free to ask lots of questions!

About the speaker: Jessica is a senior consultant at the San Francisco office of Simon-Kucher and Partners, a global strategy consulting firm specializing in advising top biotech and pharmaceutical companies. Jessica has extensive experience advising clients on commercializing cell and gene therapy technologies. She is a graduate of Harvard University.

For queries, email at weizmannbiotech@outlook.com

May 27, 2020 06:30 PM in Jerusalem

Webinar logo
Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: Weizmann Biotech Club.